Ara
Toplam kayıt 36, listelenen: 1-10
Impairment of patient-reported outcomes among patients with non-alcoholic fatty liver disease: a registry-based study
(Wiley, 2022)
Background Patients with non-alcoholic fatty liver disease (NAFLD) and more advanced fibrosis tend to have more impairment in their health-related quality of life and other patient-reported outcomes (PROs). Aim To assess ...
Geographical similarity and differences in the burden and genetic predisposition of NAFLD
(Wiley, 2022)
NAFLD has become a major public health problem for more than 2 decades with a growing prevalence in parallel with the epidemic of obesity and type 2 diabetes (T2D). The disease burden of NAFLD differs across geographical ...
Epidemiology, natural history, and diagnosis of metabolic dysfunction-associated fatty liver disease: a comparative review with nonalcoholic fatty liver disease
(Sage Publications, 2022)
Metabolic (dysfunction)-associated fatty liver disease (MAFLD) is the most common chronic liver disease worldwide – with an estimated global prevalence of 37%. Different from nonalcoholic fatty liver disease (NAFLD), which ...
Quantitative assessment of left atrial functions by speckle tracking echocardiography in hypertensive patients with and without retinopathy
(Wiley, 2022)
Purpose:The association between hypertensive retinopathy and left atrial(LA) impairment is unknown. Accordingly, it was aimed to investigate the possiblerelationship between hypertensive retinopathy and LA phasic ...
Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores
(Elsevier, 2022)
Background & Aims: Currently available non-invasive tests, including fibrosis-4 index (FIB-4) and liver stiffness measurement (LSM by VCTE), are highly effective at excluding advanced fibrosis (AF) (F ≥3) or cirrhosis in ...
An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease
(AME Publishing Company, 2023)
Background: With the rising global prevalence of fatty liver disease related to metabolic dysfunction, the association of this common liver condition with chronic kidney disease (CKD) has become increasingly evident. In ...
Asia-Pacific association for study of liver guidelines on management of ascites in liver disease
(Springer, 2023)
The development of ascites is a landmark event in the natural history of cirrhosis.
An international multidisciplinary consensus statement on MAFLD and the risk of CVD
(Springer, 2023)
Background Fatty liver disease in the absence of excessive alcohol consumption is an increasingly common condition with a global prevalence of similar to 25-30% and is also associated with cardiovascular disease (CVD). ...
Editorial: "being normal weight each day keeps NAFLD and fibrosis away"-the importance of reducing cumulative exposure to overweight
(Wiley, 2023)
The obesity epidemic is globally driving the increased prevalence of non-alcoholic fatty liver disease (NAFLD), and the vast majority of patients with NAFLD are either overweight or obese.
Pathogenetic pathways in nonalcoholic fatty liver disease: An incomplete jigsaw puzzle
(Elsevier, 2023)
Multiple pathways including insulin signaling, JNK1/2 of MAPK signaling, GLP-1R signaling, and NRs affect to maintain the homeostasis of lipid metabolism in normal liver. ERK1/2 and P38 of MAPK signaling pathway antagonistically ...